Cardiorenal syndrome.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R.
J Am Coll Cardiol. 2008 Nov 4;52(19):1527-39. doi: 10.1016/j.jacc.2008.07.051.
Gualou xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-kappaB signalling pathway.
Wang YY, Liu YY, Li J, Zhang YY, Ding YF, Peng YR.
Phytomedicine. 2024 Jan;123:155172. doi: 10.1016/j.phymed.2023.155172. Epub 2023 Oct 30.
Wnt/beta-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome.
Zhao Y, Wang C, Hong X, Miao J, Liao Y, Hou FF, Zhou L, Liu Y.
Kidney Int. 2019 Apr;95(4):815-829. doi: 10.1016/j.kint.2018.11.021. Epub 2019 Feb 12.
Cardiorenal syndrome.
Ronco C, Di Lullo L.
Heart Fail Clin. 2014 Apr;10(2):251-80. doi: 10.1016/j.hfc.2013.12.003. Epub 2014 Feb 4.
An overview of cardiovascular-kidney-metabolic syndrome.
Ferdinand KC.
Am J Manag Care. 2024 Dec;30(10 Suppl):S181-S188. doi: 10.37765/ajmc.2024.89670.
Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens-From a Cardiologist's View.
Mitsas AC, Elzawawi M, Mavrogeni S, Boekels M, Khan A, Eldawy M, Stamatakis I, Kouris D, Daboul B, Gunkel O, Bigalke B, van Gisteren L, Almaghrabi S, Noutsias M.
J Clin Med. 2022 Nov 28;11(23):7041. doi: 10.3390/jcm11237041.
[Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review].
Chávez-Iñiguez JS, Sánchez-Villaseca SJ, García-Macías LA.
Arch Cardiol Mex. 2022 Apr 4;92(2):253-263. doi: 10.24875/ACM.20000183.
The cardio-renal-metabolic connection: a review of the evidence.
Marassi M, Fadini GP.
Cardiovasc Diabetol. 2023 Jul 31;22(1):195. doi: 10.1186/s12933-023-01937-x.
Cardiorenal Syndrome Type 3 Review.
Okpara R, Pena C, Nugent K.
Cardiol Rev. 2024 Mar-Apr 01;32(2):140-145. doi: 10.1097/CRD.0000000000000491. Epub 2022 Oct 10.
Type 4 cardiorenal syndrome.
Pinheiro da Silva AL, Vaz da Silva MJ.
Rev Port Cardiol. 2016 Nov;35(11):601-616. doi: 10.1016/j.repc.2016.06.007. Epub 2016 Oct 4.
